Published in Nature on April 14, 2005
The DNA-damage response in human biology and disease. Nature (2009) 17.86
ATR: an essential regulator of genome integrity. Nat Rev Mol Cell Biol (2008) 11.86
Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol (2008) 11.43
Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer (2009) 11.25
Principles of cancer therapy: oncogene and non-oncogene addiction. Cell (2009) 10.96
GammaH2AX and cancer. Nat Rev Cancer (2008) 9.77
Signatures of mutation and selection in the cancer genome. Nature (2010) 9.75
RNF8 transduces the DNA-damage signal via histone ubiquitylation and checkpoint protein assembly. Cell (2007) 8.71
Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol (2009) 7.74
The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature (2005) 7.18
Genomic instability--an evolving hallmark of cancer. Nat Rev Mol Cell Biol (2010) 7.11
RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer (2011) 6.45
Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis. Genes Dev (2007) 6.35
The causes and consequences of genetic heterogeneity in cancer evolution. Nature (2013) 5.91
NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity (2008) 5.35
The DNA damage signaling pathway is a critical mediator of oncogene-induced senescence. Genes Dev (2007) 4.91
HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell (2008) 4.84
Nucleotide deficiency promotes genomic instability in early stages of cancer development. Cell (2011) 4.83
ATM-dependent chromatin changes silence transcription in cis to DNA double-strand breaks. Cell (2010) 4.73
53BP1 nuclear bodies form around DNA lesions generated by mitotic transmission of chromosomes under replication stress. Nat Cell Biol (2011) 4.57
Multifactorial contributions to an acute DNA damage response by BRCA1/BARD1-containing complexes. Genes Dev (2006) 4.18
A genome-wide siRNA screen reveals diverse cellular processes and pathways that mediate genome stability. Mol Cell (2009) 4.17
Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol (2008) 3.84
The MRE11 complex: starting from the ends. Nat Rev Mol Cell Biol (2011) 3.83
BRCA1 and its toolbox for the maintenance of genome integrity. Nat Rev Mol Cell Biol (2009) 3.79
Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors. Cancer Cell (2007) 3.44
Unravelling mechanisms of p53-mediated tumour suppression. Nat Rev Cancer (2014) 3.37
Comparative genomics and molecular dynamics of DNA repeats in eukaryotes. Microbiol Mol Biol Rev (2008) 3.35
Breast tumor copy number aberration phenotypes and genomic instability. BMC Cancer (2006) 3.34
BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. Nucleic Acids Res (2006) 3.29
Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining. Nat Struct Mol Biol (2010) 3.27
New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol (2008) 3.26
A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations. Nat Struct Mol Biol (2011) 3.10
Effect of NKG2D ligand expression on host immune responses. Immunol Rev (2010) 3.08
Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol (2013) 2.98
p53--a Jack of all trades but master of none. Nat Rev Cancer (2009) 2.96
PARK2 deletions occur frequently in sporadic colorectal cancer and accelerate adenoma development in Apc mutant mice. Proc Natl Acad Sci U S A (2010) 2.91
The human LINE-1 retrotransposon creates DNA double-strand breaks. J Mol Biol (2006) 2.77
Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science (2017) 2.72
RAD18 transmits DNA damage signalling to elicit homologous recombination repair. Nat Cell Biol (2009) 2.67
Role of Mre11 in chromosomal nonhomologous end joining in mammalian cells. Nat Struct Mol Biol (2009) 2.64
BRIT1 regulates early DNA damage response, chromosomal integrity, and cancer. Cancer Cell (2006) 2.61
Dysfunctional telomeres activate an ATM-ATR-dependent DNA damage response to suppress tumorigenesis. EMBO J (2007) 2.61
The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev (2009) 2.56
Telomere dysfunction and tumour suppression: the senescence connection. Nat Rev Cancer (2008) 2.54
The annealing helicase SMARCAL1 maintains genome integrity at stalled replication forks. Genes Dev (2009) 2.50
Increased Wnt signaling triggers oncogenic conversion of human breast epithelial cells by a Notch-dependent mechanism. Proc Natl Acad Sci U S A (2006) 2.49
The stress kinase MKK7 couples oncogenic stress to p53 stability and tumor suppression. Nat Genet (2011) 2.47
The bromodomain protein Brd4 insulates chromatin from DNA damage signalling. Nature (2013) 2.46
Oncogenic stress sensed by the immune system: role of natural killer cell receptors. Nat Rev Immunol (2009) 2.44
Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. Nat Struct Mol Biol (2011) 2.42
A selective requirement for 53BP1 in the biological response to genomic instability induced by Brca1 deficiency. Mol Cell (2009) 2.41
Lack of p21 expression links cell cycle control and appendage regeneration in mice. Proc Natl Acad Sci U S A (2010) 2.41
PR-Set7-dependent lysine methylation ensures genome replication and stability through S phase. J Cell Biol (2007) 2.39
ATR signalling: more than meeting at the fork. Biochem J (2011) 2.37
DNA-SCARS: distinct nuclear structures that sustain damage-induced senescence growth arrest and inflammatory cytokine secretion. J Cell Sci (2010) 2.34
ATM regulates ATR chromatin loading in response to DNA double-strand breaks. J Exp Med (2006) 2.31
DNA damage, homology-directed repair, and DNA methylation. PLoS Genet (2007) 2.29
H2AX: functional roles and potential applications. Chromosoma (2009) 2.27
Replication stress induces tumor-like microdeletions in FHIT/FRA3B. Proc Natl Acad Sci U S A (2007) 2.27
An ATM/Chk2-mediated DNA damage-responsive signaling pathway suppresses Epstein-Barr virus transformation of primary human B cells. Cell Host Microbe (2010) 2.23
Polymorphic mature microRNAs from passenger strand of pre-miR-146a contribute to thyroid cancer. Proc Natl Acad Sci U S A (2009) 2.20
ATR signaling can drive cells into senescence in the absence of DNA breaks. Genes Dev (2008) 2.17
The basic cleft of RPA70N binds multiple checkpoint proteins, including RAD9, to regulate ATR signaling. Mol Cell Biol (2008) 2.17
End-joining, translocations and cancer. Nat Rev Cancer (2013) 2.13
The p53 network: cellular and systemic DNA damage responses in aging and cancer. Trends Genet (2012) 2.13
A minimally invasive assay for individual assessment of the ATM/CHEK2/p53 pathway activity. Cell Cycle (2011) 2.13
Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers. Clin Cancer Res (2010) 2.12
Chk1 suppresses bypass of mitosis and tetraploidization in p53-deficient cancer cells. Cell Cycle (2012) 2.09
Targeting ATR and Chk1 kinases for cancer treatment: a new model for new (and old) drugs. Mol Oncol (2011) 2.07
Isoform-specific p73 knockout mice reveal a novel role for delta Np73 in the DNA damage response pathway. Genes Dev (2010) 2.06
The type 2C phosphatase Wip1: an oncogenic regulator of tumor suppressor and DNA damage response pathways. Cancer Metastasis Rev (2008) 2.06
Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers. Nat Med (2014) 2.03
Conditional HIF-1 induction produces multistage neovascularization with stage-specific sensitivity to VEGFR inhibitors and myeloid cell independence. Blood (2011) 2.02
Metformin: multi-faceted protection against cancer. Oncotarget (2011) 2.00
A hormone-DNA repair circuit governs the response to genotoxic insult. Cancer Discov (2013) 1.97
Telomere dysfunction suppresses spontaneous tumorigenesis in vivo by initiating p53-dependent cellular senescence. EMBO Rep (2007) 1.96
A GLI1-p53 inhibitory loop controls neural stem cell and tumour cell numbers. EMBO J (2009) 1.95
TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma--evidence supporting the clonal relationship of the two lesions. J Pathol (2011) 1.94
TGF-beta signaling engages an ATM-CHK2-p53-independent RAS-induced senescence and prevents malignant transformation in human mammary epithelial cells. Proc Natl Acad Sci U S A (2011) 1.94
A mitotic phosphorylation feedback network connects Cdk1, Plk1, 53BP1, and Chk2 to inactivate the G(2)/M DNA damage checkpoint. PLoS Biol (2010) 1.90
Taking the time to make important decisions: the checkpoint effector kinases Chk1 and Chk2 and the DNA damage response. DNA Repair (Amst) (2009) 1.89
Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry? Mol Cancer Res (2009) 1.87
Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell (2013) 1.86
Mouse Rif1 is a key regulator of the replication-timing programme in mammalian cells. EMBO J (2012) 1.85
ATM is down-regulated by N-Myc-regulated microRNA-421. Proc Natl Acad Sci U S A (2010) 1.85
DDB1 maintains genome integrity through regulation of Cdt1. Mol Cell Biol (2006) 1.84
ATM activation and signaling under hypoxic conditions. Mol Cell Biol (2008) 1.84
Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner. Cancer Res (2010) 1.82
Carcinogenic bacterial pathogen Helicobacter pylori triggers DNA double-strand breaks and a DNA damage response in its host cells. Proc Natl Acad Sci U S A (2011) 1.81
DNA replication stress, genome instability and aging. Nucleic Acids Res (2007) 1.80
Role of oxidatively induced DNA lesions in human pathogenesis. Mutat Res (2010) 1.78
PERK promotes cancer cell proliferation and tumor growth by limiting oxidative DNA damage. Oncogene (2010) 1.77
Maintenance of the DNA-damage checkpoint requires DNA-damage-induced mediator protein oligomerization. Mol Cell (2009) 1.73
Oncogene-induced telomere dysfunction enforces cellular senescence in human cancer precursor lesions. EMBO J (2012) 1.71
H2AX Phosphorylation: Its Role in DNA Damage Response and Cancer Therapy. J Nucleic Acids (2010) 1.69
Loss of ATM/Chk2/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas. Cancer Cell (2010) 1.68
Slx4 regulates DNA damage checkpoint-dependent phosphorylation of the BRCT domain protein Rtt107/Esc4. Mol Biol Cell (2005) 1.66
Nuclear accumulation of cyclin D1 during S phase inhibits Cul4-dependent Cdt1 proteolysis and triggers p53-dependent DNA rereplication. Genes Dev (2007) 1.65
Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors. Gastroenterology (2011) 1.64
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A (2008) 17.41
A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature (2008) 16.10
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell (2010) 12.50
Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature (2006) 11.76
BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res (2002) 8.55
Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc Natl Acad Sci U S A (2005) 8.10
A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res (2005) 7.86
Genomic instability--an evolving hallmark of cancer. Nat Rev Mol Cell Biol (2010) 7.11
Methylated lysine 79 of histone H3 targets 53BP1 to DNA double-strand breaks. Nature (2004) 6.72
A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell (2010) 6.47
A promoter-level mammalian expression atlas. Nature (2014) 6.25
Lung cancer susceptibility locus at 5p15.33. Nat Genet (2008) 5.99
Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res (2008) 5.95
Embryonic stem cell-specific microRNAs promote induced pluripotency. Nat Biotechnol (2009) 5.14
Chromosomal microarray versus karyotyping for prenatal diagnosis. N Engl J Med (2012) 4.97
Generation of induced pluripotent stem cells in the absence of drug selection. Cell Stem Cell (2007) 4.94
Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther (2006) 4.57
53BP1 functions in an ATM-dependent checkpoint pathway that is constitutively activated in human cancer. Nat Cell Biol (2002) 4.45
Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res (2003) 4.28
Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res (2006) 4.20
Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res (2003) 4.03
Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res (2004) 3.62
Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis. Mol Cell Biol (2003) 3.51
Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res (2006) 3.42
Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat Genet (2011) 3.10
Axis of evil: molecular mechanisms of cancer metastasis. Oncogene (2003) 2.81
SCFbetaTrCP-mediated degradation of Claspin regulates recovery from the DNA replication checkpoint response. Mol Cell (2006) 2.75
The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res (2008) 2.64
Epidermal growth factor receptor mediates increased cell proliferation, migration, and aggregation in esophageal keratinocytes in vitro and in vivo. J Biol Chem (2002) 2.58
The stress kinase MKK7 couples oncogenic stress to p53 stability and tumor suppression. Nat Genet (2011) 2.47
Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell (2013) 2.43
Activation of Notch1 signaling is required for beta-catenin-mediated human primary melanoma progression. J Clin Invest (2005) 2.38
Life isn't flat: taking cancer biology to the next dimension. In Vitro Cell Dev Biol Anim (2006) 2.32
Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res (2002) 2.21
In vitro fertilization with single euploid blastocyst transfer: a randomized controlled trial. Fertil Steril (2013) 2.15
Isolation of a novel population of multipotent adult stem cells from human hair follicles. Am J Pathol (2006) 2.13
Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression. Cancer Res (2006) 2.12
Transcription factor E2F-1 acts as a growth-promoting factor and is associated with adverse prognosis in non-small cell lung carcinomas. J Pathol (2002) 2.04
Rewired ERK-JNK signaling pathways in melanoma. Cancer Cell (2007) 2.03
PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas. Pigment Cell Melanoma Res (2010) 2.02
The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front Biosci (2005) 2.00
Incidence and spectrum of chromosome abnormalities in spontaneous abortions: new insights from a 12-year study. Genet Med (2005) 1.98
Association between a 15q25 gene variant, smoking quantity and tobacco-related cancers among 17 000 individuals. Int J Epidemiol (2009) 1.97
Hypomethylation of retrotransposable elements correlates with genomic instability in non-small cell lung cancer. Int J Cancer (2009) 1.94
Accurate single cell 24 chromosome aneuploidy screening using whole genome amplification and single nucleotide polymorphism microarrays. Fertil Steril (2010) 1.93
Transcribed enhancers lead waves of coordinated transcription in transitioning mammalian cells. Science (2015) 1.91
Break-induced replication repair of damaged forks induces genomic duplications in human cells. Science (2013) 1.90
Up-regulated expression of zonula occludens protein-1 in human melanoma associates with N-cadherin and contributes to invasion and adhesion. Am J Pathol (2005) 1.88
Noninvasive prenatal aneuploidy testing of chromosomes 13, 18, 21, X, and Y, using targeted sequencing of polymorphic loci. Prenat Diagn (2012) 1.88
Emerging common themes in regulation of PIKKs and PI3Ks. EMBO J (2009) 1.88
53BP1 and NFBD1/MDC1-Nbs1 function in parallel interacting pathways activating ataxia-telangiectasia mutated (ATM) in response to DNA damage. Cancer Res (2003) 1.87
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther (2008) 1.86
Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma. J Mol Diagn (2007) 1.85
53BP1, an activator of ATM in response to DNA damage. DNA Repair (Amst) (2004) 1.84
Functional interaction between BLM helicase and 53BP1 in a Chk1-mediated pathway during S-phase arrest. J Cell Biol (2004) 1.82
Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma. J Clin Invest (2014) 1.81
An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells. Cancer Res (2007) 1.81
Deregulated overexpression of hCdt1 and hCdc6 promotes malignant behavior. Cancer Res (2007) 1.79
Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res (2002) 1.78
Crystal structure of the FHA domain of the Chfr mitotic checkpoint protein and its complex with tungstate. Structure (2002) 1.77
Influence of common genetic variation on lung cancer risk: meta-analysis of 14 900 cases and 29 485 controls. Hum Mol Genet (2012) 1.77
Adhesion, migration and communication in melanocytes and melanoma. Pigment Cell Res (2005) 1.76
Nuclear cyclin D1/CDK4 kinase regulates CUL4 expression and triggers neoplastic growth via activation of the PRMT5 methyltransferase. Cancer Cell (2010) 1.76
Suppression of nucleotide metabolism underlies the establishment and maintenance of oncogene-induced senescence. Cell Rep (2013) 1.74
Detecting and targeting mesenchymal-like subpopulations within squamous cell carcinomas. Cell Cycle (2011) 1.70
A subpopulation of mouse esophageal basal cells has properties of stem cells with the capacity for self-renewal and lineage specification. J Clin Invest (2008) 1.69
A genome-wide association study of upper aerodigestive tract cancers conducted within the INHANCE consortium. PLoS Genet (2011) 1.68
Tumors as elusive targets of T-cell-based active immunotherapy. Trends Immunol (2003) 1.67
Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells. Cancer Res (2007) 1.64
Defective apoptosis and B-cell lymphomas in mice with p53 point mutation at Ser 23. EMBO J (2004) 1.63
Differential response of primary and metastatic melanomas to neutrophils attracted by IL-8. Int J Cancer (2003) 1.62
External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds. Oncologist (2011) 1.59
Oncogene-induced senescence: the bright and dark side of the response. Curr Opin Cell Biol (2010) 1.58
Periostin, a cell adhesion molecule, facilitates invasion in the tumor microenvironment and annotates a novel tumor-invasive signature in esophageal cancer. Cancer Res (2010) 1.58
Karyotype versus microarray testing for genetic abnormalities after stillbirth. N Engl J Med (2012) 1.56
Genomic imbalances in pediatric patients with chronic kidney disease. J Clin Invest (2015) 1.56
Melanoma-stroma interactions: structural and functional aspects. Lancet Oncol (2002) 1.55
The Chfr mitotic checkpoint protein functions with Ubc13-Mms2 to form Lys63-linked polyubiquitin chains. Oncogene (2003) 1.55
BRAF as a potential therapeutic target in melanoma and other malignancies. Cancer Cell (2003) 1.55
Growth index is independent of microvessel density in non-small-cell lung carcinomas. Hum Pathol (2002) 1.53